There is still time to join us on a sign on action letter to the FDA regarding it’s judgement to delay access to the prostate cancer treatment, Provenge, at www.malecare.com With more new drugs set for FDA consideration this summer, a strong showing of Prostate Cancer patients is vital. Please take a look and if [...]
Spectrum Pharmaceuticals announces that the FDA's Oncology Drug Advisory Committee (ODAC) will review their very promising investigational drug Satraplatin for the Treatment of Hormone Refractory Prostate Cancer. The hearing will be held on July 24, 2007. This is very exciting, especially in light of the FDA’s surprising failure to approve Provenge. A quick review of [...]
In today’s Wall Street Journal there is a fantastic opinion piece written by Dr. Mark Thornton, Black Wednesday at the FDA. Dr. Thornton points out that not only did the FDA not approve Provenge last Wednesday, but also it failed to approve Junovan, a immunological drug designed to treat young children with a rare bone [...]
The Wall Street Journal's health blog has exploded with comments about the recent article about the FDA and Provenge. Their piece along with the comments are a must read. You can see the blog at: The Wall Street Journal Health Blog Please don't forget to www.malecare.com and sign our letter to the FDA. Our letter [...]
There is a sign on action letter to the FDA regarding it's CR letter on Provenge, at www.malecare.com Please take a look and if you agree, sign on. Also, please help get the word out about this, as we will mail this letter and its signatories on May 18, 2007.
I woke this morning feeling very angry and much stressed. One of the principles in cancer management is to reduce, ideally remove stress from ones life. Now the FDA is adding stress, major stress to my life. When I heard about the FDA action I was disappointed, but not angry. As the evening went on [...]
The controversy that has been haunting the FDA approval of Provenge (sipuleucel-T) still continues with major fireworks on all sides. I have written a number of pieces about Provenge in this blog, so if you are not familiar with this potential new treatment you might want to go back and read them. Pay particular attention [...]
There was just a symposium held at Methodist Hospital in Houston. The day long symposium covered both prostate cancer and kidney cancer. Barbara Christensen attended the kidney cancer side of the lectures and has been publishing on a kidney cancer listserv a summary of the information of what she learned. I think that her first [...]
Clarifying the Issues Surrounding Dendreon's Provenge Posted on Apr 16th, 2007 with stocks: DNDN Wall Diver submits: Rebuttal to article, "Dendreon's Provenge Apart by ODAC Member": On April 13, 2007, in Volume 33, No. 14 of The Cancer Letter, a letter was published which the Editor, Paul Goldberg, attributed to Howard Scher, MD, of the [...]
Dr. Howard Scher, M.D. was one of the four members of the Provenge advisory committee who voted against recommending that the FDA approve Provenge. Dr. Scher is a respected clinician (practicing at Sloane Kettering Hospital) and researcher. I do believe that his letter contributes to the discussion about Povenge and so I have chosen to [...]
